

10-12-2000

To the Honorable Commissioner of  
Patents and Trademarks:  
Please record the attached original  
document or copy thereof.

9.25.00



101485886

<p>1. Name of party or parties conveying an interest: Helsinki University Licensing Ltd. Oy.</p>	<p>2. Name and address of party or parties receiving an interest: Name: Ludwig Institute for Cancer Research, a Swiss not-for-profit corporation Address: 605 Third Avenue City: New York State: New York Zip: 10158</p>
<p>3. Description of the interest conveyed:</p> <p><input checked="" type="checkbox"/> Assignment (50% interest)      Other: _____  <input type="checkbox"/> Merger  <input type="checkbox"/> Change of Name  <input type="checkbox"/> Security Agreement</p> <p>Execution Date: Feb. 3, 2000</p>	
<p>4. Application number(s) or patent number(s). Additional sheet attached? YES _____ NO <u>X</u></p> <p>A. Patent application no.(s): 09/375,248 filed Aug. 16, 1999</p>	<p>If the document is being filed together with a new application, the execution date of the application is: _____</p> <p>B. Patent no.(s): _____</p>
<p>5. Name and address of party to whom correspondence concerning this cover sheet should be mailed: Name: David A. Gass Reg. No. 38,153 MARSHALL, O'TOOLE, GERSTEIN, MURRAY &amp; BORUN Street Address: 6300 Sears Tower, 233 South Wacker Drive City: Chicago State: Illinois Zip: 60606-6402</p>	<p>6. Number of applications and/or patents identified on this cover sheet: <u>1</u></p> <p>7. Amount of fee enclosed or authorized to be charged: \$ 40.00</p> <p>8. Any additional required fee may be charged, or any overpayment credited to our deposit account: 13-2855</p>

9. To the best of my knowledge and belief, the information contained on this cover sheet is true and correct and any copy submitted is a true copy of the original document.

Date: Sept 20, 2000

David A. Gass

David A. Gass  
Reg. No. 38,153

10/11/2000 MTHAI1 00000256 09375248

01 FC:581

Total number of pages including cover sheet, attachments, and document: 3

PATENT  
REEL: 011139 FRAME: 0607

Atty. Docket No.: 28967/35255A

**ASSIGNMENT**

WHEREAS, Helsinki University Licensing Ltd. Oy., Viikinkaari 6, FIN-00710 Helsinki, Finland (hereinafter HUL), its successors and assigns, is the assignee of the entire right, title and interest in the invention or improvements of Kari Alitalo and Marika Karkkainen relating to screening and therapy for lymphatic disorders involving the Flt-4 receptor tyrosine kinase (VEGFR-3) disclosed in U.S. Patent Application Serial No. 09/375,248 and in International Patent Application No. PCT/US99/06133 and in Canadian Patent Application No. 2283470, and in said applications and any and all other applications, both United States and other countries which Kari Alitalo and Marika Karkkainen may file, either solely or jointly with others, on said invention or improvements, and in any and all Letters Patent of the United States and other countries, which may be obtained on any of said applications, and in any reissue or extension thereof; and

WHEREAS, for ten dollars (\$10.00), and other good and valuable consideration, the sufficiency of which is hereby acknowledged, HUL has agreed to share ownership of its interest in the aforementioned invention, improvements, applications, patents, reissues, extensions, and the like on a 50%/50% equal basis with Ludwig Institute for Cancer Research, a Swiss not-for-profit corporation, having offices at 605 Third Avenue, New York, New York 10158 (hereinafter LICR);

NOW, THEREFORE, HUL hereby assigns to LICR a fifty percent (50%) interest in the patent applications identified in the following LIST OF PATENTS PROPERTIES, and in all Letters Patent of the United States and other countries, which may be obtained on any of said patent applications, and in any reissue or extension thereof.

LIST OF PATENT PROPERTIES

<u>Application No.</u>	<u>Filing Date</u>	<u>Title</u>
U.S.S.N. 09/375,248	08/16/99	Screening and Therapy for Lymphatic Disorders Involving the Flt-4 Receptor Tyrosine Kinase (VEGFR-3)
PCT/US99/06133	03/26/99	Screening and Therapy for Lymphatic Disorders Involving the Flt-4 Receptor Tyrosine Kinase (VEGFR-3)
Canada 2283470	09/29/99	Screening and Therapy for Lymphatic Disorders Involving the Flt-4 Receptor Tyrosine Kinase (VEGFR-3)

WITNESS my hand this \_\_\_\_\_ day of \_\_\_\_\_, year \_\_\_\_\_.

Witnesses:

Helsinki University Licensing Ltd. Oy.

1) *Taina Savisa*  
Name: TAINA SAVISA

*Eija Pöytäki*  
Eija Pöytäki  
Managing Director

2) *Maria Järnström*  
Name: MARIA JÄRNSTRÖM